Gilead Sciences (NASDAQ:GILD) Given New $105.00 Price Target at Wells Fargo & Company
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lifted by Wells Fargo & Company from $100.00 to $105.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently weighed in on the company. Needham […]
More Stories
Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued...
Tesla (NASDAQ:TSLA) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says
Tesla (NASDAQ:TSLA – Get Free Report) had its price target upped by analysts at Royal Bank of Canada from $249.00...
HIVE Digital Technologies (NASDAQ:HIVE) Stock Price Expected to Rise, Northland Securities Analyst Says
HIVE Digital Technologies (NASDAQ:HIVE – Free Report) had its price target boosted by Northland Securities from $5.50 to $7.00 in...
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00
Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price increased by Citigroup from $55.00 to $60.00 in a research...
Hims & Hers Health (NYSE:HIMS) Lowered to “Underperform” Rating by Bank of America
Bank of America downgraded shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a buy rating to an...
Morgan Stanley Forecasts Strong Price Appreciation for Smurfit Westrock (NYSE:SW) Stock
Smurfit Westrock (NYSE:SW – Free Report) had its price objective lifted by Morgan Stanley from $60.00 to $64.00 in a...